FinVector’s new gene therapy manufacturing hub opened in Kuopio

On October 3rd in Kuopio, the biotechnology company FinVector celebrated the opening of Finport, a global gene therapy manufacturing hub. The new state-of-the-art facility specializes in the production of Adstiladrin, an FDA-approved gene therapy drug for non-muscle invasive bladder cancer.

FinVector is a privately owned subsidiary of Ferring Ventures S/A, a gene and cell therapy focused investment and development holding company. Both FinVector and Ferring Ventures Oy are part of the same consortium and draw from the pioneering research of Professor Seppo Ylä-Herttuala.

For more information, see the press releases from FinVector or UEF.